These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 12107547

  • 21. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 22. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M, Olive M, Reed E, O'Connell B, Vinson C.
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [Abstract] [Full Text] [Related]

  • 23. Analysis of microsatellite instability in acquired drug-resistance human tumor cell lines.
    Picard SF, Franco N, Sergent C, Chauffert B, Lizard-Nacol S.
    Oncol Rep; 2002 Jan; 9(5):971-6. PubMed ID: 12168057
    [Abstract] [Full Text] [Related]

  • 24. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs.
    Cinatl J, Cinatl J, Kotchetkov R, Matousek J, Woodcock BG, Koehl U, Vogel JU, Kornhuber B, Schwabe D.
    Anticancer Res; 2000 Jan; 20(2A):853-9. PubMed ID: 10810366
    [Abstract] [Full Text] [Related]

  • 25. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M.
    Anticancer Res; 1998 Jan; 18(2A):927-33. PubMed ID: 9615743
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53.
    Keshelava N, Tsao-Wei D, Reynolds CP.
    Clin Cancer Res; 2003 Aug 15; 9(9):3492-502. PubMed ID: 12960142
    [Abstract] [Full Text] [Related]

  • 28. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A, Seth K, Kalra N, Shukla Y.
    Toxicol Appl Pharmacol; 2005 Feb 01; 202(3):237-43. PubMed ID: 15667829
    [Abstract] [Full Text] [Related]

  • 29. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 01; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 30. Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
    Lavie Y, Harel-Orbital T, Gaffield W, Liscovitch M.
    Anticancer Res; 2001 Jul 01; 21(2A):1189-94. PubMed ID: 11396162
    [Abstract] [Full Text] [Related]

  • 31. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.
    Ireland CM, Pittman SM, Jones SL, Harnett PR.
    Anticancer Res; 1994 Jul 01; 14(6B):2397-403. PubMed ID: 7872659
    [Abstract] [Full Text] [Related]

  • 32. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M.
    Prostate; 2007 Jun 15; 67(9):955-67. PubMed ID: 17440963
    [Abstract] [Full Text] [Related]

  • 33. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.
    Lotfi K, Månsson E, Peterson C, Eriksson S, Albertioni F.
    Biochem Biophys Res Commun; 2002 May 24; 293(5):1489-96. PubMed ID: 12054684
    [Abstract] [Full Text] [Related]

  • 34. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M.
    Anticancer Res; 1994 May 24; 14(5A):1995-2003. PubMed ID: 7847840
    [Abstract] [Full Text] [Related]

  • 35. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 24; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 36. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
    Zhou J, Cheng SC, Luo D, Xie Y.
    Biochem Biophys Res Commun; 2001 Feb 09; 280(5):1237-42. PubMed ID: 11162660
    [Abstract] [Full Text] [Related]

  • 37. [Establishment of a cisplatin-induced human hepatocellular carcinoma drug-resistant cell line and its biological characteristics].
    Yang JX, Tang WX.
    Ai Zheng; 2002 Aug 09; 21(8):872-6. PubMed ID: 12478896
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines.
    Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T.
    Clin Cancer Res; 1996 Feb 09; 2(2):427-32. PubMed ID: 9816187
    [Abstract] [Full Text] [Related]

  • 40. [Establishment and drug-resistance gene expression of cisplatin-resistant cell line Tca8113/CDDP].
    Zhou XJ, Li Q, Chen WT.
    Shanghai Kou Qiang Yi Xue; 2003 Dec 09; 12(6):432-5. PubMed ID: 14966583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.